title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Monday,20220418T154044,https://www.benzinga.com/news/22/04/26669813/stocks-that-hit-52-week-lows-on-monday,XBIT,0.005428,Neutral,-0.023
Stocks That Hit 52-Week Lows On Thursday,20220331T181044,https://www.benzinga.com/news/22/03/26401822/stocks-that-hit-52-week-lows-on-thursday,XBIT,0.02511,Neutral,-0.000461
Stocks That Hit 52-Week Lows On Tuesday,20220426T174457,https://www.benzinga.com/markets/options/22/04/26818122/52-weeks-high-and-low-article,XBIT,0.00928,Neutral,0.008049
Stocks That Hit 52-Week Lows On Monday,20220425T160100,https://www.benzinga.com/markets/options/22/04/26791205/52-weeks-high-and-low-article,XBIT,0.008154,Neutral,0.00537
Stocks That Hit 52-Week Lows On Monday,20220516T175917,https://www.benzinga.com/markets/options/22/05/27226401/52-weeks-high-and-low-article,XBIT,0.026147,Neutral,-0.035642
Stocks That Hit 52-Week Lows On Tuesday,20220524T161351,https://www.benzinga.com/markets/options/22/05/27375519/52-weeks-high-and-low-article,XBIT,0.010175,Neutral,-0.01865
74 Biggest Movers From Yesterday,20220429T091949,https://www.benzinga.com/news/22/04/26890965/74-biggest-movers-from-yesterday,XBIT,0.047711,Neutral,0.005734
Stocks That Hit 52-Week Lows On Thursday,20220421T175401,https://www.benzinga.com/markets/options/22/04/26742233/52-weeks-high-and-low-article,XBIT,0.021637,Neutral,0.003813
Stocks That Hit 52-Week Lows On Monday,20220314T161153,https://www.benzinga.com/news/22/03/26125409/stocks-that-hit-52-week-lows-on-monday,XBIT,0.003772,Neutral,-0.000744
Stocks That Hit 52-Week Lows On Thursday,20220310T165722,https://www.benzinga.com/news/22/03/26083670/stocks-that-hit-52-week-lows-on-thursday,XBIT,0.014015,Neutral,0.001049
Stocks That Hit 52-Week Lows On Thursday,20220602T172744,https://www.benzinga.com/markets/options/22/06/27526024/52-weeks-high-and-low-article,XBIT,0.053402,Neutral,0.052285
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,XBIT,0.041466,Neutral,0.013857
